Management of Dyslipidemia Associated With Protease Inhibitors

American Journal of Cardiology

Volumn 103, Issue 2, 2009, Pages 292-293

  Kapoor, John R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; CHOLESTEROL; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; LOW DENSITY LIPOPROTEIN; METFORMIN; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TRIACYLGLYCEROL;

CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LETTER; PRIORITY JOURNAL; RHABDOMYOLYSIS; UNSPECIFIED SIDE EFFECT; VIROLOGY;

CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; HIV; HIV INFECTIONS; HUMANS; INCIDENCE; PROTEASE INHIBITORS; RISK FACTORS;

EID: 58049177502     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.10.014     Document Type: Letter

References (9)

1. Manfredi R., and Chiodo F. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs and role of hypolipidaemic therapy with bezafibrate. J Infect 42 (2001) 181-188
2. Khunnawat C., Mukerji S., Havlichek Jr. D., Touma R., and Abela G.S. Cardiovascular manifestations in human immunodeficiency virus-infected patients. Am J Cardiol 102 (2008) 635-642
3. Dubé M.P., Stein J.H., Aberg J.A., Fichtenbaum C.J., Gerber J.G., Tashima K.T., Henry W.K., Currier J.S., Sprecher D., and Glesby M.J. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 37 (2003) 613-627
4. Miller J., Brown D., Amin J., Kent-Hughes J., Law M., Kaldor J., Cooper D.A., and Carr A. A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia. AIDS 16 (2002) 2195-2200
5. Périard D., Telenti A., Sudre P., Cheseaux J.J., Halfon P., Reymond M.J., Marcovina S.M., Glauser M.P., Nicod P., Darioli R., and Mooser V. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 100 (1999) 700-705
6. Haas D.W., Zala C., Schrader S., Piliero P., Jaeger H., Nunes D., Thiry A., Schnittman S., Sension M., and Protocol AI424-009 Study Group. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial. AIDS 17 (2003) 1339-1349
7. Wood R., Phanuphak P., Cahn P., Pokrovskiy V., Rozenbaum W., Pantaleo G., Sension M., Murphy R., Mancini M., Kelleher T., and Giordano M. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. J Acquir Immune Defic Syndr 36 (2004) 684-692
8. Murphy R.L., Sanne I., Cahn P., Phanuphak P., Percival L., Kelleher T., and Giordano M. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS 17 (2003) 2603-2614
9. Sanne I., Piliero P., Squires K., Thiry A., and Schnittman S. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr 32 (2003) 18-29